Compare MMSI & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MMSI | PBLS |
|---|---|---|
| Founded | 1987 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 3.6B |
| IPO Year | 1996 | 2026 |
| Metric | MMSI | PBLS |
|---|---|---|
| Price | $87.26 | $38.17 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $98.88 | N/A |
| AVG Volume (30 Days) | 449.0K | ★ 549.9K |
| Earning Date | 04-30-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 4.93 | N/A |
| EPS | ★ 1.33 | N/A |
| Revenue | ★ $1,515,906,000.00 | N/A |
| Revenue This Year | $8.85 | N/A |
| Revenue Next Year | $5.88 | N/A |
| P/E Ratio | $64.28 | ★ N/A |
| Revenue Growth | ★ 11.75 | N/A |
| 52 Week Low | $59.74 | $25.56 |
| 52 Week High | $94.75 | $42.49 |
| Indicator | MMSI | PBLS |
|---|---|---|
| Relative Strength Index (RSI) | 41.97 | 47.73 |
| Support Level | $85.19 | $26.42 |
| Resistance Level | $92.22 | $41.34 |
| Average True Range (ATR) | 2.06 | 2.68 |
| MACD | -0.67 | -0.30 |
| Stochastic Oscillator | 16.75 | 29.21 |
Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment which consists of cardiology and radiology medical device products that assist in diagnosing and treating coronary artery disease, peripheral vascular disease, and other non-vascular diseases and includes embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, and interventional oncology and spine devices.
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.